Information Provided By: 
Fly News Breaks for September 15, 2017
AMED
Sep 15, 2017 | 08:15 EDT
After attending meetings with management, Oppenheimer analyst Michael Wiederhorn says Amedisys' business is performing well. The company's core operations are well positioned into the back half of the year, with business development efforts expected to benefit admission trends, Wiederhorn tells investors in a research note. He takes a constructive view on the shares, while admitting there is a "major overhang" from the Medicare proposal for 2019. The analyst keeps an Outperform rating on Amedisys with a $60 price target.
News For AMED From the Last 2 Days
There are no results for your query AMED
